Although ET is the recommended treatment for most patients with ER+/HER2– MBC, a substantial proportion received CT, possibly due to the high prevalence of visceral disease in the study population. Median TTP on current therapies is < 1 year. These findings suggest a continuing unmet need for new treatments that extend TTP.
Real-world treatment patterns and clinical outcomes in Er+/Her2- metastatic breast cancer
Results from a multicountry retrospective medical record review